1-18 of 18
Elizabeth A. Punnoose
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Detection of Early Molecular Response (EMR) and Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using a Validated Next Generation Sequencing (NGS) Assay for the Detection of Tumor Variants in Circulating Tumor (ct)DNA

Renee P Stokowski, Ehsan Tabari, Patrick Bogard, Coleen Hacker, Olga K Kameneva, Tieming Ji, Li Teng, Vladislava Melnikova, Ron McCord, Elizabeth A Punnoose, Robert Loberg, Junaid Shabbeer
Journal: Blood
Blood (2022) 140 (Supplement 1): 9257–9258.
https://doi.org/10.1182/blood-2022-162814
Published: 2022
Journal Articles

A Novel Transcriptomic Classifier for AML Is Highly Associated with Drug Sensitivity

Habib Hamidi, Christopher R Bolen, Elisabeth A Lasater, Diana Dunshee, Elizabeth A Punnoose, Monique Dail
Journal: Blood
Blood (2021) 138 (Supplement 1): 2372.
https://doi.org/10.1182/blood-2021-153395
Published: 2021
Journal Articles

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Ian W. Flinn, Sam L. S. Yuen, Max S. Topp, Chiara Rusconi, Isabelle Fleury, Katell Le Dû, Christopher Arthur, Barbara Pro, Giuseppe Gritti, Michael Crump, Adam Petrich, Divya Samineni, Arijit Sinha, Elizabeth A. Punnoose, Edith Szafer-Glusman, Nathalie Spielewoy, Mehrdad Mobasher, Kathryn Humphrey, Martin Kornacker, Wolfgang Hiddemann
Journal: Blood
Blood (2020) 136 (23): 2628–2637.
https://doi.org/10.1182/blood.2020005588
Published: 2020
Includes: Supplemental data
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019
Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Philippe Moreau, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Michael E O'Dwyer, MD, Mamta Garg, MD FRCP, FRCPath, Elizabeth A Punnoose, PhD, Muhammad Jalaluddin, PhD, Jia Jia, PhD MBA, Xiaoqing Yang, PhD, Yan Sun, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 142.
https://doi.org/10.1182/blood-2019-126094
Published: 2019
Journal Articles

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Francesca Gay, MD, Gábor Mikala, MD PhD, Elizabeth A Punnoose, PhD, Wan-Jen Hong, MD, Anjla Sood, MD, Muhammad Jalaluddin, PhD, Jeremy A. Ross, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1888.
https://doi.org/10.1182/blood-2019-126015
Published: 2019
Journal Articles

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Clinical Trials & Observations
Magdalena Klanova, Laurie H. Sehn, Isabelle Bence-Bruckler, Federica Cavallo, Jie Jin, Maurizio Martelli, Douglas Stewart, Umberto Vitolo, Francesco Zaja, Qingyuan Zhang, Federico Mattiello, Gila Sellam, Elizabeth A. Punnoose, Edith Szafer-Glusman, Christopher R. Bolen, Mikkel Z. Oestergaard, Guenter R. Fingerle-Rowson, Tina Nielsen, Marek Trneny
Journal: Blood
Blood (2019) 133 (9): 919–926.
https://doi.org/10.1182/blood-2018-07-862862
Published: 2019
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Sam Yuen, Max S. Topp, Chiara Rusconi, Isabelle Fleury, Christopher K Arthur, Barbara Pro, MD, Giuseppe Gritti, MD PhD, Michael Crump, Katell Le Du, MD, Divya Samineni, Arijit Sinha, Elizabeth A Punnoose, Edith Szafer-Glusman, Nathalie Danesi, Adam Petrich, Martin Kornacker, Kathryn Humphrey, Mehrdad Mobasher, MD MPH, Wolfgang Hiddemann
Journal: Blood
Blood (2018) 132 (Supplement 1): 1614.
https://doi.org/10.1182/blood-2018-99-116806
Published: 2018
Journal Articles

MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, MBBS, PhD, Thomas J. Kipps, MD PhD, Barbara Eichhorst, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, James D'Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, MD PhD, Javier de la Serna, Ulrich Jaeger, MD, Guillaume Cartron, Marco Montillo, MD, Nicole Lamanna, MD, Maria E. Verdugo, Elizabeth A Punnoose, Yanwen Jiang, Jue Wang, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, MD MPH, Arnon P. Kater, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 184.
https://doi.org/10.1182/blood-2018-184
Published: 2018
Journal Articles

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Franck Morschhauser, Pierre Feugier, Ian W. Flinn, MD PhD, Robin E Gasiorowski, Richard Greil, MD, Árpád Illés, Nathalie A Johnson, MDPhD, Jean-Francois Larouche, Pieternella J Lugtenburg, Caterina Patti, Gilles Salles, MD PhD, Marek Trněný, Sven de Vos, Farheen Mir, MBBS, Martin Kornacker, Elizabeth A Punnoose, Divya Samineni, Edith Szafer-Glusman, Adam Petrich, Arijit Sinha, Mehrdad Mobasher, MD MPH, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 782.
https://doi.org/10.1182/blood-2018-99-118519
Published: 2018
Journal Articles

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Arnon P. Kater, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Barbara Eichhorst, Anton W Langerak, Thomas J. Kipps, MD PhD, Carolyn Owen, Michelle Boyer, Kathryn Humphrey, Elizabeth A Punnoose, Jue Wang, Brenda Chyla, Maria E. Verdugo, Jenny Wu, Yanwen Jiang, Mehrdad Mobasher, MD MPH, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 185.
https://doi.org/10.1182/blood-2018-99-117050
Published: 2018
Journal Articles

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

Elisabeth A Lasater, PhD, An D Do, Luciana Burton, Yijin Li, Erin Williams, Jason Oeh, Luciana Molinero, Elicia Penuel, Deepak Sampath, Monique Dail, Marcia Belvin, Teiko Sumiyoshi, Elizabeth A Punnoose, Jeffrey Venstrom, Aparna Raval
Journal: Blood
Blood (2018) 132 (Supplement 1): 1118.
https://doi.org/10.1182/blood-2018-99-116405
Published: 2018
Journal Articles

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Clinical Trials & Observations
Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mikhael, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, Thierry Facon, Martine Amiot, Philippe Moreau, Elizabeth A. Punnoose, Stefanie Alzate, Martin Dunbar, Tu Xu, Suresh K. Agarwal, Sari Heitner Enschede, Joel D. Leverson, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo, Cyrille Touzeau
Journal: Blood
Blood (2017) 130 (22): 2401–2409.
https://doi.org/10.1182/blood-2017-06-788786
Published: 2017
Includes: Supplemental data
Journal Articles

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Clinical Trials & Observations
Philippe Moreau, Asher Chanan-Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, Shaji Kumar, Cyrille Touzeau, Elizabeth A. Punnoose, Jaclyn Cordero, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Kevin J. Freise, Joel D. Leverson, Sari Heitner Enschede, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo, Simon J. Harrison
Journal: Blood
Blood (2017) 130 (22): 2392–2400.
https://doi.org/10.1182/blood-2017-06-788323
Published: 2017
Includes: Supplemental data
Journal Articles

A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax

Jenny Wu, Jeremy Ross, Franklin V. Peale, Jr., John D Shaughnessy, Jr., PhD, Ryan K Van Laar, PhD, Gareth J Morgan, MD PhD, Jeffrey M Venstrom, Elizabeth A. Punnoose, PhD
Journal: Blood
Blood (2016) 128 (22): 5613.
https://doi.org/10.1182/blood.V128.22.5613.5613
Published: 2016
Journal Articles

Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

Pier Luigi Zinzani, MD PhD, Max S Topp, MD, Sam LS Yuen, MBBS, FRCPA, FRACP, Chiara Rusconi, MD, Isabelle Fleury, MD MSc, FRCPC, Barbara Pro, MD, Giuseppe Gritti, MD, Michael Crump, MD, Wanling Hsu, MS, Elizabeth A. Punnoose, PhD, James Hilger, PhD, Mehrdad Mobasher, MD, Wolfgang Hiddermann, MD
Journal: Blood
Blood (2016) 128 (22): 617.
https://doi.org/10.1182/blood.V128.22.617.617
Published: 2016
Journal Articles

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, MD, Guillaume Cartron, MD PhD, Michael Hallek, Barbara F. Eichhorst, MD, Mark Kozloff, MD, Thomas A. Giever, Gerard Lozanski, MD, Elizabeth A. Punnoose, PhD, Jue Wang, James Hilger, PhD, Mehrdad Mobasher, MD, Gilles Salles, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4393.
https://doi.org/10.1182/blood.V128.22.4393.4393
Published: 2016
Journal Articles

Mutation Load and a Functional T Effector Signature May Distinguish Immunologically Distinct and Clinically Relevant Lymphoma Subsets

Chris Bolen, PhD, Ronald McCord, PhD, Garrett Frampton, PhD, Richard Bourgon, PhD, Elizabeth A. Punnoose, PhD, Edith Szafer-Glusman, PhD, Pierre Sujobert, MD PhD, Luc Xerri, MD PhD, Sarah Huet, PharmD, PhD, Gilles Salles, MD PhD, Jeffrey M Venstrom
Journal: Blood
Blood (2016) 128 (22): 913.
https://doi.org/10.1182/blood.V128.22.913.913
Published: 2016